ES2090956T3 - Imidazolil o imidazolilalquil sustituido con un anillo heterociclico de cuatro o cinco miembros que contiene nitrogeno. - Google Patents

Imidazolil o imidazolilalquil sustituido con un anillo heterociclico de cuatro o cinco miembros que contiene nitrogeno.

Info

Publication number
ES2090956T3
ES2090956T3 ES93901329T ES93901329T ES2090956T3 ES 2090956 T3 ES2090956 T3 ES 2090956T3 ES 93901329 T ES93901329 T ES 93901329T ES 93901329 T ES93901329 T ES 93901329T ES 2090956 T3 ES2090956 T3 ES 2090956T3
Authority
ES
Spain
Prior art keywords
compound
formula
pct
disclosed
imidazolyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93901329T
Other languages
English (en)
Inventor
Neng-Yang Shih
Robert Aslanian
Andrew Lupo Jr
John J Piwinski
Michael J Green
Ashit K Ganguly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2090956T3 publication Critical patent/ES2090956T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

ES DESCUBIERTO UN COMPONENTE DE FORMULA (I) O UNA SAL ACEPTABLE FARMACEUTICAMENTE O SOLVATE DE ELLO. TAMBIEN SON DESCUBIERTAS LAS COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN PORTADOR ACEPTABLE FARMACEUTICAMENTE Y UNA CANTIDAD EFECTIVA DE UN COMPONENTE DE FORMULA (I) . ADEMAS ES DESCUBIERTO UN METODO DE TRATAR LA ALERGIA (POR EJEMPLO ASMA), INFLAMACION, HIPERTENSION, PRESION INTRAOCULAR ELEVADA (POR EJEMPLO GLAUCOMA)--POR EJEMPLO, UN METODO DE REBAJAR LA PRESION INTRAOCULAR, DESORDENES DE SUEÑO, ESTADOS DE HIPER E HIPO MOTILIDAD Y SECRECION ACIDICAS DEL APARATO GASTROINTESTINAL, HIPO E HIPERACTIVIDAD DEL SISTEMA NERVIOSO CENTRAL (POR EJEMPLO, AGITACION Y DEPRESION) Y OTROS DESORDENES CNS (TALES COMO ALZHEIMERS, SCHIZOPHRENIA, Y JAQUECA) COMPRENDIENDO ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN COMPONENTE DE FORMULA (I) A UN PACIENTE EN LA NECESIDAD DE TAL TRATAMIENTO.
ES93901329T 1991-12-18 1992-12-17 Imidazolil o imidazolilalquil sustituido con un anillo heterociclico de cuatro o cinco miembros que contiene nitrogeno. Expired - Lifetime ES2090956T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80978191A 1991-12-18 1991-12-18

Publications (1)

Publication Number Publication Date
ES2090956T3 true ES2090956T3 (es) 1996-10-16

Family

ID=25202205

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93901329T Expired - Lifetime ES2090956T3 (es) 1991-12-18 1992-12-17 Imidazolil o imidazolilalquil sustituido con un anillo heterociclico de cuatro o cinco miembros que contiene nitrogeno.

Country Status (20)

Country Link
US (1) US5463074A (es)
EP (1) EP0618913B1 (es)
JP (1) JPH07121939B2 (es)
KR (1) KR0142802B1 (es)
AT (1) ATE141269T1 (es)
AU (1) AU671092B2 (es)
CA (1) CA2129679C (es)
DE (1) DE69212844T2 (es)
DK (1) DK0618913T3 (es)
ES (1) ES2090956T3 (es)
GR (1) GR3021464T3 (es)
HK (1) HK31397A (es)
IL (1) IL104125A (es)
MX (1) MX9207393A (es)
MY (1) MY110108A (es)
NZ (1) NZ246441A (es)
SG (1) SG44510A1 (es)
TW (1) TW268950B (es)
WO (1) WO1993012108A1 (es)
ZA (1) ZA929788B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633250A (en) * 1991-12-18 1997-05-27 Schering Corporation Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
EP0842172A1 (en) * 1995-06-29 1998-05-20 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
EP0891360A4 (en) * 1996-04-03 2002-05-15 Merck & Co Inc FARNESYL PROTEIN TRANSFERASE INHIBITORS
JP2000507597A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼ阻害剤
US6072057A (en) * 1996-06-06 2000-06-06 Gliatech Inc. 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H3 receptor agents
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
US6034251A (en) * 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
IL135727A0 (en) * 1997-11-07 2001-05-20 Schering Corp Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
US6028095A (en) * 1998-10-15 2000-02-22 Warner-Lambert Company Treatment of inflammatory bowel disease using histamine H3 -receptor agonists
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
US6100279A (en) * 1998-11-05 2000-08-08 Schering Corporation Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
EP1147092A1 (en) 1999-01-18 2001-10-24 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
WO2002072093A2 (en) 2001-02-08 2002-09-19 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
EP1373251A2 (en) 2001-03-13 2004-01-02 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
FR2827863A1 (fr) * 2001-07-27 2003-01-31 Sanofi Synthelabo Derives d'aminoalkylimidazole, leur preparation et leur utilisation en therapeutique
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717233A1 (en) * 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
EP1968940B1 (en) 2005-12-30 2014-04-02 Novartis AG 3 , 5-substitued piperidine compounds as renin inhibitors
EP2527338B1 (en) 2007-06-25 2015-05-06 Novartis AG N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987522A (en) * 1958-03-17 1961-06-06 Petrolite Corp Amidine products
US3491098A (en) * 1967-05-29 1970-01-20 Sterling Drug Inc 1-((imidazolyl)-lower-alkyl)-4-substituted-piperazines
US3470197A (en) * 1967-08-30 1969-09-30 Miles Lab 1-substituted derivatives of 3-ethyl-4 - (1-methylimidazolyl-(5)-methyl)-2-pyrrolidinone
US4011238A (en) * 1972-07-26 1977-03-08 Gruppo Lepetit S.P.A. 2-imidazolidione derivatives
DE2862340D1 (en) * 1978-02-01 1983-11-24 Wellcome Found Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof
GR73560B (es) * 1979-02-24 1984-03-15 Pfizer
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4404382A (en) * 1980-09-17 1983-09-13 The Upjohn Company Piperazinyl-substituted imidazoles
US4404387A (en) * 1980-09-17 1983-09-13 The Upjohn Company Aminoalkyl-substituted imidazoles
US4431653A (en) * 1982-03-18 1984-02-14 Hoffmann-La Roche Inc. Penicillanic acid derivatives
DE3313073A1 (de) * 1983-04-12 1984-10-18 Bayer Ag, 5090 Leverkusen 1-azolyl-3-pyrazolyl-2-propanol-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US4581370A (en) * 1983-07-12 1986-04-08 Schering A.G. Antiarrhythmic imidazoliums
DK704488D0 (da) * 1988-12-19 1988-12-19 Novo Industri As Nye n-substituerede azaheterocykliske carboxylsyrer
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
US5010075A (en) * 1987-04-24 1991-04-23 Syntex Pharmaceuticals Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4935417A (en) * 1987-04-24 1990-06-19 Syntex Pharmaceuticals Ltd. Sustituted imidazolyl-alkyl-piperazine and -diazepine derivatives for treating cerebrovascular disease
US5091428A (en) * 1987-04-24 1992-02-25 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
DE3811574A1 (de) * 1988-03-31 1989-10-19 Schering Ag N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
FR2630328B1 (fr) * 1988-04-22 1990-08-24 Inst Nat Sante Rech Med Derive de l'histamine, sa preparation et son application en therapeutique
US4925851A (en) * 1989-05-23 1990-05-15 Sandoz Pharmaceuticals Corp. 2- or 4-substituted-[2-(1H-imidazol-1-yl)ethyl]piperidines
US5264449A (en) * 1989-11-13 1993-11-23 Allergan, Inc. N-substituted derivatives of 3R,4R-ethyl-[(1-methyl-1H-imidazol-5-yl)methyl]-2-pyrrolidinone
US5066663A (en) * 1990-05-21 1991-11-19 Warner-Lambert Company Substituted-hetero-cyclopentanones and cyclopentenones and derivatives thereof acting at muscarinic receptors
BR9306190A (pt) * 1992-04-01 1998-06-23 Univ Toledo Composto composiçao farmacéutica e processo para tratar um indivíduo sofrendo de um distúrbio cognitivo ou uma deficiéncia na atençao ou estímulo

Also Published As

Publication number Publication date
TW268950B (es) 1996-01-21
MY110108A (en) 1998-01-27
EP0618913B1 (en) 1996-08-14
MX9207393A (es) 1994-06-30
ZA929788B (en) 1993-06-22
JPH07121939B2 (ja) 1995-12-25
DE69212844D1 (de) 1996-09-19
AU3277393A (en) 1993-07-19
CA2129679C (en) 2000-05-09
DK0618913T3 (da) 1996-10-14
IL104125A0 (en) 1993-05-13
WO1993012108A1 (en) 1993-06-24
KR0142802B1 (en) 1998-07-15
SG44510A1 (en) 1997-12-19
IL104125A (en) 2000-08-31
NZ246441A (en) 1996-02-27
DE69212844T2 (de) 1997-01-09
EP0618913A1 (en) 1994-10-12
AU671092B2 (en) 1996-08-15
CA2129679A1 (en) 1993-06-24
ATE141269T1 (de) 1996-08-15
JPH06511009A (ja) 1994-12-08
GR3021464T3 (en) 1997-01-31
US5463074A (en) 1995-10-31
HK31397A (en) 1997-03-21
KR940703826A (es) 1994-12-12

Similar Documents

Publication Publication Date Title
ES2090956T3 (es) Imidazolil o imidazolilalquil sustituido con un anillo heterociclico de cuatro o cinco miembros que contiene nitrogeno.
ES2089782T3 (es) Imidazolalquilo sustituido con un anillo heterociclico que contiene nitrogeno de seis elementos.
TW268951B (es)
WO1999024421A8 (en) Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom
NO20044698L (no) Statinterapi for a oke kognitiv opprettholdelse
ATE170527T1 (de) Phosphonobernsteinsäurederivate und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 618913

Country of ref document: ES

FG2A Definitive protection

Ref document number: 618913

Country of ref document: ES